Anne Altmeyer sold $22k of CRBP
director at Corbus Pharmaceuticals Holdings, Inc.. 1,060 shares at an average of $20.50, traded Oct 20, 2025, filed Oct 21, 2025.
Score components
- +15RoleDirector
- 0Trade size$22k at market
- +5Share of holdings soldSold 15% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-245262, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 20, 2025 | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +1,060 | $4.80 | $5,088 | 7,251 | Oct 21, 2025 |
| Oct 20, 2025 | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -1,060 | $20.50 | $22k | 6,191 | Oct 21, 2025 |
| Oct 20, 2025 | MOption exercise Stock options (right to buy)derivative10b5-1 | -1,060 | $0.00 | $0 | 4,247 | Oct 21, 2025 |
Related signals
Other insiders at Corbus Pharmaceuticals Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Corbus Pharmaceuticals Holdings, Inc. | Yong Ben director | $16k 2,000 shares | -18% | |
| 30Weak | Corbus Pharmaceuticals Holdings, Inc. | Dominic Smethurst Chief Medical Officer | $51k 6,097 shares | -6% | |
| 30Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $108k 13,871 shares | -7% | |
| 23Weak | Corbus Pharmaceuticals Holdings, Inc. | Sean F. Moran Chief Financial Officer | $37k 4,701 shares | -5% | |
| 35Weak | Corbus Pharmaceuticals Holdings, Inc. | Ian Hodgson Chief Operating Officer | $6,253 847 shares | -2% | |
| 35Weak | Corbus Pharmaceuticals Holdings, Inc. | Ian Hodgson Chief Operating Officer | $20k 2,415 shares | -4% | |
| 35Weak | Corbus Pharmaceuticals Holdings, Inc. | Dominic Smethurst Chief Medical Officer | $27k 3,285 shares | -3% | |
| 27Weak | CRBPsell Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP owner | $344k 30,029 shares | -1% | |
| 27Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $471k 27,633 shares | -18% | |
| 19Weak | Corbus Pharmaceuticals Holdings, Inc. | Sean F. Moran Chief Financial Officer | $221k 12,981 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.